Sonnet BioTherapeutics Publishes Key Data On SON-1010 IL-12 Fusion Protein In Frontiers In Immunology, Highlighting Mechanism Of Action And Enhanced Tumor Targeting With Patents Secured Through 2039
Sonnet BioTherapeutics Publishes Key Data On SON-1010 IL-12 Fusion Protein In Frontiers In Immunology, Highlighting Mechanism Of Action And Enhanced Tumor Targeting With Patents Secured Through 2039
Sonnet BioTherapeutics在《免疫学前沿》上发表关于SON-1010 IL-12融合蛋白的关键数据，突出了其作用机制和增强的肿瘤靶向性，并获得了到2039年的专利保护。
Sonnet BioTherapeutics Publishes Key Data On SON-1010 IL-12 Fusion Protein In Frontiers In Immunology, Highlighting Mechanism Of Action And Enhanced Tumor Targeting With Patents Secured Through 2039
Sonnet BioTherapeutics 在《免疫学前沿》上公布了关于 SON-1010 IL-12 融合蛋白的关键数据，强调了其作用机制和通过专利增强肿瘤靶向的能力，专利有效期至2039年。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
资讯热榜
更新时间